Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Journal of Biopharmaceutical Statistics|January 8, 2014
Subgroups: time to go back to basic statistical principles?Oliver N Keene, Andrew D GarrettPharmaceutical Statistics|October 30, 2018
Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reductionOliver N KeenePharmaceutical Statistics|March 4, 2010
Intent-to-treat analysis in the presence of off-treatment or missing dataOliver N KeeneStatistics in Medicine|November 19, 2002
Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trialsOliver N KeenePharmaceutical Statistics|November 4, 2006
Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert GroupAlan J Phillips, Oliver N Keene, Pharmaceutical Statistics|February 10, 2010
Statistical resource needs to be increased in the European regulatory agenciesOliver N Keene, Sara H Hughes, Nigel Howitt, et al.Pharmaceutical Statistics|July 12, 2022
The cross-over of statistical thinking and practices: A pandemic catalystAndrew D GarrettStatistics in Medicine|February 15, 2003
Therapeutic equivalence: fallacies and falsificationAndrew D GarrettRespiratory Medicine|May 4, 2019
Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μLSteven W Yancey, Eric S Bradford, Oliver N KeeneContemporary Clinical Trials|June 29, 2021
Why ITT analysis is not always the answer for estimating treatment effects in clinical trialsOliver N Keene, David Wright, Alan Phillips, et al.Pageof 4